Autoimmune liver diseases (AILDs), including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing ...
We read with interest the Rome Foundation paediatric global study by Nurko and colleagues,1 which establishes a multinational ...
Background The impact of circulating tumour DNA (ctDNA) detection, which informs minimal residual disease (MRD) after ...
Background Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in ...
Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid cancers, portending poor patient outcomes ...
Background Hospitalisations represent major clinical events in cirrhosis, yet prediction based on clinical variables alone ...
Eosinophilic gastritis (EoG) is a rare, chronic disease characterised by pathological eosinophilia of the stomach and gastrointestinal symptoms. Evidence suggests that pathophysiology is triggered by ...
The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy ...
Recent work in Gut has highlighted multi-kingdom interactions between gut bacteria and bacteriophage (‘phage’) as contributors to Crohn’s disease.1 Whether similar alterations characterise colorectal ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Background The liver naturally exhibits robust glycosylation processes, yet how aberrant glycosylation affects hepatocellular carcinoma (HCC) and its underlying mechanisms remains poorly understood.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results